The shadow of generic challenges has long loomed around copyright’s blockbuster drug, Viagra, raising questions about the future of related pharmaceutical holdings. While early periods saw impressive gains, the intellectual property lapse has created the door for less website expensive substitutes, likely reducing revenue and posing a real danger